NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 11437.25 -159.65 -1.38%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Protalix BioTherapeutics, Inc. (AMEX: PLX)

 
PLX Technical Analysis
4
As on 31st Oct 2017 PLX Share Price closed @ 0.78 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.77 & Strong Buy for SHORT-TERM with Stoploss of 0.61 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

PLX Share Price

Open 0.71 Change Price %
High 0.80 1 Day 0.08 11.43
Low 0.70 1 Week 0.00 0.00
Close 0.78 1 Month 0.20 34.48
Volume 2551481 1 Year 0.30 62.50
52 Week High 1.51 | 52 Week Low 0.26
 
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
NGD 3.29 -6.80%
RBY 0.03 -70.00%
LODE 0.12 -7.69%
PBTH 8.23 0.37%
GGR 0.02 100.00%
VTG 0.05 -16.67%
SYRG 8.13 0.87%
GSX 0.02 0.00%
SHZ 0.10 -16.67%
 
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
 
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
LBY 6.84 -25.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
 
 
PLX
Daily Charts
PLX
Intraday Charts
Whats New @
Bazaartrend
PLX
Free Analysis
 
PLX Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE0.87
RESISTANCE0.83
SUPPORT0.73
SUPPORT0.69
SUPPORT0.00
SUPPORT0.00
 
PLX Target for Month July
4th UP TARGET1.47
3rd UP TARGET1.25
2nd UP TARGET1.11
1st UP TARGET0.98
1st DOWN TARGET0.58
2nd DOWN TARGET0.45
3rd DOWN TARGET0.31
4th DOWN TARGET0.09
 
PLX Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
PLX Target for Year 2019
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
PLX Other Details
Segment EQ
Market Capital 441232352.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.protalix.com
 
PLX Address
PLX
2 Snunit Street
Science Park
Carmiel, 21000
Israel
Phone: 972 4 988 9488
Fax: 972 4 988 9489
 
PLX Latest News
 
Your Comments and Response on Protalix BioTherapeutics, Inc.
 
PLX Business Profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant glucocerebrosidase enzyme produced and encapsulated within carrot cells; and PRX-106, an oral antiTNF, a plant cell expressed recombinant fusion protein combined of the binding domain of the human TNF receptor and an antibody portion, which is being developed for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, colitis, Crohn’s disease, psoriasis, and other autoimmune and inflammatory disorders. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and PRX-107, a proprietary plant cell recombinant human Alpha1-antitrypsin and others. The company has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.
 
2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service